Taming the dragon: genomic biomarkers to individualize the treatment of cancer.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 21386834.
- Also identified by DOI 10.1038/nm.2311.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The gradual shift from cytotoxic drugs to highly selective, targeted therapeutic agents for cancer requires a parallel effort to characterize cancers at the molecular level to guide the choice of therapy for the individual patient. Here we review the genomic technologies that can be used to develop these drug response indicators, or biomarkers. We also discuss hurdles in their development and the implementation of biomarkers in clinical practice.
Medical subject headings
- Biomarkers, Tumor
- Genomics
- Neoplasms